<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380106</url>
  </required_header>
  <id_info>
    <org_study_id>RV-MM-PI-0345</org_study_id>
    <nct_id>NCT01380106</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma</brief_title>
  <official_title>A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Pittsburgh Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Greater Los Angeles Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael E. DeBakey VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edward Hines Jr. VA Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to evaluate two different Lenalidomide doses (15 mg vs. 25 mg) in&#xD;
      combination with low dose dexamethasone in patients with relapsed multiple myeloma.&#xD;
&#xD;
      The investigators propose to use the need for dose reduction as a criterion to judge&#xD;
      tolerability from various causes. In the veteran population which predominantly is in the&#xD;
      older age category with number of co-morbidities, a lower dose regimen may be safer and&#xD;
      advantageous.&#xD;
&#xD;
      This study expects to enroll approximately 80 subjects from participating VA sites across the&#xD;
      nation.&#xD;
&#xD;
      The investigators will evaluate the safety of the two dose regimens by comparing frequency of&#xD;
      dose reductions. The investigators will also measure how long the responses last with each&#xD;
      dose.&#xD;
&#xD;
      Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment of&#xD;
      specific types of myelodysplastic syndrome (MDS) and in combination with dexamethasone for&#xD;
      patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM&#xD;
      are cancers of the blood. It is currently being tested in a variety of cancer conditions. In&#xD;
      this case it is considered experimental.&#xD;
&#xD;
      At the time of enrollment, one-half of the subjects will be chosen at random to receive the&#xD;
      15 mg Lenalidomide dose and the other half will take the 25 mg dose regimen of Lenalidomide.&#xD;
      Depending on lenalidomide treatment assignment, subjects will receive either 15 mg p.o. q.d.&#xD;
      or 25 mg p.o. q.d. for days 1-21 of a 28 day cycle. In addition, dexamethasone (40 mg) will&#xD;
      be added once a week (Days 1, 8, 15 and 22) to the Lenalidomide regimen, with a dose&#xD;
      reduction on the same schedule if the patient cannot tolerate the higher dose of&#xD;
      dexamethasone. ASA (81 or 325mg) will be given daily for anticoagulation prophylaxis.&#xD;
      Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended.&#xD;
      Coumadin will be allowed provided the patient is fully anticoagulate with INR 2.0 to 2.5.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • Evaluate the frequency of dose reductions in two different lenalidomide dose regimens.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Evaluate the efficacy of two different lenalidomide dose regimens in patients with&#xD;
           multiple myeloma using the EBMT and IMWG criteria.&#xD;
&#xD;
        -  Evaluate the duration of response of 15 mg Lenalidomide and 25 mg of Lenalidomide when&#xD;
           used in combination with Low Dose Dexamethasone.&#xD;
&#xD;
        -  Evaluate the safety of 15 mg and 25 mg of Lenalidomide regiments when in combination&#xD;
           with dexamethasone.&#xD;
&#xD;
        -  Explore blood and cellular levels of angiogenic factors, cytokines, and adhesion&#xD;
           molecules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 11, 2017</completion_date>
  <primary_completion_date type="Actual">September 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.</time_frame>
    <description>Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.&#xD;
SAE Grade 3 indicates a severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization; disabling; limiting self care ADL SAE Grade 4 indicates a life-threatening consequences; urgent intervention indicated.&#xD;
SAE Grade 5 Death related to AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration Until Best Response (at Least MR or Minimal Response)</measure>
    <time_frame>Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.</time_frame>
    <description>Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide 15mg</intervention_name>
    <description>Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
    <arm_group_label>Lenalidomide 15mg</arm_group_label>
    <other_name>REVLIMID®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide 25mg</intervention_name>
    <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
    <arm_group_label>Lenalidomide 25mg</arm_group_label>
    <other_name>REVLIMID®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously diagnosed with multiple myeloma.&#xD;
&#xD;
          2. Must have relapsed or refractory disease (refractory is defined as progression during&#xD;
             treatment or within 60 days after the completion of treatment) requiring 2nd or 3rd&#xD;
             line therapy&#xD;
&#xD;
          3. Patients may have received lenalidomide and/or dexamethasone&#xD;
&#xD;
          4. Patients must have measurable disease:&#xD;
&#xD;
               -  Serum monoclonal protein &gt;0.5g/dL and/or 0.2g/24hr urine light chain excretion&#xD;
&#xD;
               -  Patients with lower M-protein values or non-secretory myeloma will be eligible if&#xD;
                  measurable disease can be established, such as serum FreeliteTM chain ratio &gt;5x&#xD;
                  ULN, measurable soft tissue plasmacytoma &gt;2cm by either physical exam and/or&#xD;
                  applicable radiographs (i.e. MRI, CT-scan) and/or bone marrow involvement &gt;30%&#xD;
&#xD;
          5. Age &gt;=18 years at the time of consent.&#xD;
&#xD;
          6. All necessary baseline studies for determining eligibility must be obtained within 14&#xD;
             days prior to enrollment. Serum pregnancy tests (sensitivity of at least 25 mIU/mL),&#xD;
             for females of childbearing potential (WCBP) must be completed. The first test must be&#xD;
             performed within 10-14 days, and the second test within 24 hours prior to initiation&#xD;
             of lenalidomide.&#xD;
&#xD;
          7. Pre-study ECOG performance status 0-2. Patients with lower performance status based&#xD;
             solely on bone pain will be eligible.&#xD;
&#xD;
          8. Adequate liver functions: AST and ALT =&lt; 3xULN, alkaline phosphatase =&lt; 3.0x ULN,&#xD;
             except if attributed to tumor, and bilirubin =&lt; 2xULN.&#xD;
&#xD;
          9. Have Amylase =&lt; 2.5x ULN&#xD;
&#xD;
         10. Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
         11. Must understand and voluntarily sign an informed consent document.&#xD;
&#xD;
         12. Females of childbearing potential (FCBP)† must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 50 mIU/mL 10 - 14 days prior to and&#xD;
             again within 24 hours of starting lenalidomide and must either commit to continued&#xD;
             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth&#xD;
             control, one highly effective method and one additional effective method AT THE SAME&#xD;
             TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to&#xD;
             ongoing pregnancy testing. Men must agree not to father a child and agree to use a&#xD;
             condom if his partner is of child bearing potential. All patients must be counseled at&#xD;
             a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.&#xD;
&#xD;
         13. All study participants must be registered into the mandatory RevAssist® program, and&#xD;
             be willing and able to comply with the requirements of RevAssist®. All counseling will&#xD;
             be done through RevAssist®.&#xD;
&#xD;
         14. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. Patients&#xD;
             intolerant to ASA may use low molecular weight heparin. Lovenox is recommended.&#xD;
             Coumadin will be allowed provided the patient is fully anticoagulate with INR 2.0 to&#xD;
             2.5.&#xD;
&#xD;
         15. Patients may receive a bisphosphonate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          2. Pregnant or breast feeding females.(Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          3. Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          4. Renal insufficiency of creatinine clearance &lt;40mL/min&#xD;
&#xD;
          5. Known hypersensitivity to thalidomide or lenalidomide.&#xD;
&#xD;
          6. Development of erythema nodosum if characterized by a desquamating rash while taking&#xD;
             thalidomide or similar drugs.&#xD;
&#xD;
          7. Concurrent use of other anti-cancer agents or treatments.&#xD;
&#xD;
          8. Known seropositive for an active viral infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible.&#xD;
&#xD;
          9. Has hemoglobin &lt;8.0g/dL. The use of transfusion with pRBC to correct anemia and meet&#xD;
             eligibility criteria will not be allowed.&#xD;
&#xD;
         10. Has an absolute neutrophil count &lt;1.0x10^9/L within 14 days before enrollment&#xD;
&#xD;
         11. Peripheral neuropathy of grade &gt;=3. Patients with painful grade 2 neuropathy are also&#xD;
             excluded&#xD;
&#xD;
         12. Has platelet count &lt;75x10^9/L within 14 days before enrollment.&#xD;
&#xD;
         13. Plasma cell leukemia at time of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil C Munshi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston VA Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Los Angeles VA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh VA Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston VA Research Institute, Inc.</investigator_affiliation>
    <investigator_full_name>Nikhil Munshi, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator -- Coordinating site</investigator_title>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Revlimid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT01380106/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide 25mg</title>
          <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
        </group>
        <group group_id="P2">
          <title>Lenalidomide 15mg</title>
          <description>Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>33</population>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide 25mg</title>
          <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
        </group>
        <group group_id="B2">
          <title>Lenalidomide 15mg</title>
          <description>Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>M-protein</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.12" lower_limit=".47" upper_limit="6.9"/>
                    <measurement group_id="B2" value="2.74" lower_limit="0" upper_limit="6.9"/>
                    <measurement group_id="B3" value="2.93" lower_limit="0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.&#xD;
SAE Grade 3 indicates a severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization; disabling; limiting self care ADL SAE Grade 4 indicates a life-threatening consequences; urgent intervention indicated.&#xD;
SAE Grade 5 Death related to AE.</description>
        <time_frame>Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.</time_frame>
        <population>33</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide 25mg</title>
            <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 15mg</title>
            <description>Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.&#xD;
SAE Grade 3 indicates a severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization; disabling; limiting self care ADL SAE Grade 4 indicates a life-threatening consequences; urgent intervention indicated.&#xD;
SAE Grade 5 Death related to AE.</description>
          <population>33</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration Until Best Response (at Least MR or Minimal Response)</title>
        <description>Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).</description>
        <time_frame>Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.</time_frame>
        <population>33</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide 25mg</title>
            <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 15mg</title>
            <description>Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration Until Best Response (at Least MR or Minimal Response)</title>
          <description>Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).</description>
          <population>33</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.4" lower_limit="86.6" upper_limit="474.3"/>
                    <measurement group_id="O2" value="145.5" lower_limit="75.7" upper_limit="215.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide 25mg</title>
          <description>Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle</description>
        </group>
        <group group_id="E2">
          <title>Lenalidomide 15mg</title>
          <description>Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle&#xD;
Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Coronary ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alpha strep infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Potassium level change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Low calcium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastric Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypercapnic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>GERD (suspected)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nikhil C. Munshi, M.D.</name_or_title>
      <organization>Boston VA Research Institute, Inc.</organization>
      <phone>6176325607</phone>
      <email>nikhil.munshi@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

